DRUG
Get informed when a big investor buys or sells
+ FollowOvervalued by 85.1% based on the discounted cash flow analysis.
| Market cap | $596.82 Million |
|---|---|
| Enterprise Value | $288.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.78 |
| Beta | 0.09 |
| Outstanding Shares | 9,830,424 |
| P/E Ratio | -29.48 |
|---|---|
| PEG | 55.58 |
| Price to Sales | - |
| Price to Book Ratio | 1.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.32 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 94.90%▼ 0.91% |
|---|---|
| Total Invested | $655.06M▼ 2.27% |
| Investors Holding | 102▲ 8.00% |
No data